When mycophenolic acid (MPA) was originally marketed for immunosuppressive therapy,
fixed doses were recommended by the manufacturer. Awareness of the potential for a more …

Many studies have shown that the efficacy and risk of side effects of drug treatment is
influenced by genetic variants. Evidence based guidelines are essential for implementing …

Translating CYP 2D6 genotype to metabolizer phenotype is not standardized across clinical
laboratories offering pharmacogenetic (PGx) testing and PGx clinical practice guidelines …

The purpose of this guideline is to provide information for the interpretation of clinical
dihydropyrimidine dehydrogenase (DPYD) genotype tests so that the results can be used to …

Abstract CYP2D6 and CYP2C19 polymorphisms affect the exposure, efficacy and safety of
tricyclic antidepressants (TCAs), with some drugs being affected by CYP2D6 only (eg …

Next-generation sequencing (NGS) technology has expanded in the last decades with
significant improvements in the reliability, sequencing chemistry, pipeline analyses, data …

After decades of discovery, inherited variations have been identified in approximately 20
genes that affect about 80 medications and are actionable in the clinic. And some …

Abstract The Dutch Pharmacogenetics Working Group (DPWG) aims to facilitate
pharmacogenetics implementation in clinical practice by developing evidence-based …

Since its clinical introduction in 1998, the topoisomerase I inhibitor irinotecan has been
widely used in the treatment of solid tumors, including colorectal, pancreatic, and lung …

The implementation of pharmacogenomic (PGx) testing in psychiatry remains modest, in part
due to divergent perceptions of the quality and completeness of the evidence base and …